🇺🇸 CycloSPORINE Ophthalmic in United States
23 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 23
Most-reported reactions
- Vision Blurred — 4 reports (17.39%)
- Dizziness — 3 reports (13.04%)
- Condition Aggravated — 2 reports (8.7%)
- Eye Irritation — 2 reports (8.7%)
- Fall — 2 reports (8.7%)
- Gastrooesophageal Reflux Disease — 2 reports (8.7%)
- Pain — 2 reports (8.7%)
- Pain In Extremity — 2 reports (8.7%)
- Tremor — 2 reports (8.7%)
- Type 2 Diabetes Mellitus — 2 reports (8.7%)
CycloSPORINE Ophthalmic in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Ophthalmology approved in United States
Frequently asked questions
Is CycloSPORINE Ophthalmic approved in United States?
CycloSPORINE Ophthalmic does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for CycloSPORINE Ophthalmic in United States?
Université de Sherbrooke is the originator. The local marketing authorisation holder may differ — check the official source linked above.